Abstract. Sulforaphane (SFN) is an isothiocyanate present in cruciferous vegetables, which has been shown to exert an anti-cancer effect when tested in vitro and in vivo. The anti-cancer effects of SFN encompass induction of cytoprotective autophagy; therefore, the present study aimed to determine whether the chemopreventive activity of SFN may be potentiated by inhibition of autophagy. The present study provided detailed insight into the susceptibility of human neuroblastoma cells to treatment with synthetic SFN, in combination with an inhibitor of autophagy, 3-methyladenine (3-MA). The present study confirmed the suppression of the viability of the human neuroblastoma cell line BE(2)-C by SFN and reported the inhibition of DNA synthesis, as determined by a decrease in tritiated thymidine incorporation. Furthermore, the results verified the effectiveness of SFN in inducing apoptosis in the BE(2)-C cell line as demonstrated by caspase activation, increased protein expression levels of B-cell lymphoma 2-associated X protein and loss of mitochondrial membrane potential. Combined treatment of the cells with SFN with 3-MA proved to be effective in decreasing cell viability, through a mechanism that may proceed via the early induction of autophagy by SFN, followed by induction of apoptosis, as well as inhibition of autophagy by 3-MA.
Introduction
Sulforaphane, [1-isothiocyanato-4-(methylsulfinyl)-butane; (SFN)] is an isothiocyanate compound found in cruciferous vegetables, including broccoli and cauliflower. SFN is a well-known cancer chemopreventive agent, which may also influence normal cells (1) . Two putative mechanisms of action underlying the anti-cancer effect of isothiocyanates have been identified. The first mechanism is based on the activation of the phase 2 detoxification enzymes, such as glutathione S-transferase, and/or the simultaneous inhibition of the phase 1 enzymes, such as cytochrome P450 isoenzyme 2E1, which may be responsible for the anti-carcinogenic activity (2, 3) . Upregulation of phase 2 enzymes, including glutathione transferases, protects cells against carcinogens and has previously been shown to prevent carcinogen-induced tumors in various animal models (1, 2, 4) . The second mechanism refers to the suppression of tumor development by the induction of apoptosis, growth inhibition and cell cycle arrest (5) (6) (7) (8) . At the molecular level, the protective properties of SFN rely on activation of the pro-apoptotic B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), resulting in apoptosis of endothelial progenitor cells and consequently reducing tumor growth (9) . In addition, SFN has been shown to inhibit histone deacetylase activity and cause histone hyperacetylation in cancer cells, including human colon cancer (10) .
The induction of apoptosis by SFN has previously been observed in numerous cancer models, including the prostate cancer cell lines PC-3 and LNCaP (8) and the human colon cancer cell line HT29 (5) . However, the exact mechanism underlying the induction of apoptosis by SFN remains to be elucidated. SFN-induced apoptosis in human prostate cancer cell lines was shown to be initiated by the production of reactive oxygen species (ROS) (7, 11) . In addition, caspase 8 is associated with SFN-induced apoptosis and its activity depends on ROS production (7) .
SFN was previously reported to induce autophagy in prostate cancer cell lines, which provided protection against the induction of apoptosis by SFN (8 HENRYK KOŁOCZEK 3 and HANNA ROKITA function of autophagy is to maintain a natural balance between existing and forthcoming synthesized proteins and organelles. Autophagy literally means 'self-eating' and is a process of cellular self-digestion which may lead to cell death (12) . The process of digesting organelles and molecules occurs in double-membrane autophagosomes (13) . The protein beclin-1 interacts with a class III phosphatidyl-inositol 3-kinase (PI3K) and initiates autophagosomal membrane assembly (14) . Furthermore, microtubule-associated protein light chain 3 (MAP-LC3 or LC3) is incorporated into the autophagosome membrane, which may be tracked until fusion with the lysosome vesicle (15) . MAP-LC3 exists in two forms: cytoplasmic LC3-I (18 kDa) and autophagosome-associated LC3-II (16 kDa), which has undergone proteolytic cleavage (16) . In the PC-3 prostate cancer cell line, SFN causes redistribution of LC3 into autophagosomes and 3-methyladenine (3-MA), an inhibitor of autophagy, is able to restrain this process (8) . The adenine analogue blocks class III PI3K complex activities and the mammalian target of rapamycin pathway, leading to the inhibition of autophagy (17) . The present study used the BE(2)-C human neuroblastoma cell line containing the amplified MYCN gene (responsible for high levels of aggressiveness) and P53 mutation, to characterize the effects of synthetic SFN on cells in vitro. The effects of SFN on caspase activity, the mitochondrial membrane potential and Bax levels were also investigated. The results of the present study confirmed the effectiveness of SFN in the induction of apoptosis in the BE(2)-C cell line as well as its ability to induce early autophagy. The present study showed that the combined treatment of the cells with SFN with 3-MA enhanced cell death.
Materials and methods
Reagents. D,L-Sulforaphane was synthesized at the University of Agriculture (Kraków, Poland), according to the method by Schmidt and Karrer (18) . Purification of the compound was performed by high-performance liquid chromatography and the identity of the SFN was verified by nuclear magnetic resonance and ultraviolet spectroscopy. A stock solution of SFN (7.2 M in serum-free medium) was stored at -20˚C until further use. SFN was diluted with culture medium immediately prior to use. 3-MA, staurosporine (STS) and antibodies against GAPDH (G8795) were purchased from Sigma-Aldrich (Poznań, Poland). Trypsin (0.25%) was obtained from Gibco Life Technologies (Carlsbad, CA, USA), and (6-3 H) thymidine was from GE Healthcare Life Sciences (Little Chalfont, UK). Rabbit antibodies against LC3B (3868) and beclin-1 (3495) were purchased from Cell Signaling Technology (Danvers, MA, USA). An antibody against Bcl-2 (sc-783) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA) and an antibody against Bax (556467) was obtained from BD Pharmingen (San Diego, CA, USA). Secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) (A0545) and anti-mouse IgG antibodies (A9044) were obtained from Sigma-Aldrich. The secondary anti-rabbit IgG HRP-linked antibodies (7074) were from Cell Signaling Technology. All of the other chemicals and reagents used in the experiments of the present study were of analytical grade.
Cell culture. The BE(2)-C human neuroblastoma cell line was obtained from the American Type Culture Collection (Manassas, VA, USA; ATCC number, CRL-2268). The BE(2)-C cell line is a clone of the SK-N-BE(2) neuroblastoma cell line. The cells were cultured in a 1:1 mixture of Eagle's minimum essential medium and F12 medium, supplemented with 10% fetal calf serum, 1% non-essential amino acid solution, 1 mM sodium pyruvate and 50 µg/ml gentamicin (all from Sigma Aldrich) at 37˚C in an atmosphere containing 5% CO 2 .
MTT assay. The MTT assay is based on the ability of living cells to reduce the MTT tetrazolium salt to MTT formazan by the mitochondrial enzyme succinate dehydrogenase (19) . The BE(2)-C cells (2.5x10 4 /well) were cultured in 96-well plates for 24 h and treated with increasing concentrations of synthetic SFN for the indicated time periods. MTT (Sigma-Aldrich) was added to each well to a final concentration of 0.5 mg/ml. Following a 4-h incubation at 37˚C, the formazan crystals were dissolved in isopropanol containing 5 mM HCl. The absorbance was measured at wavelengths of 570 and 630 nm using the SpectraMax 250 microplate reader (Molecular Devices, Sunnyvale, CA, USA). The 50% maximal inhibitory concentration (IC 50 ) was defined as the concentration that resulted in a 50% decrease in the absorbance of the SFN-treated cells, as compared with the media-grown cells. In separate experiments, the BE(2)-C cells (2.5x10 4 /well) were cultured in 96-well plates for 24 h. The medium was then removed and the cells were treated with either 40 µM synthetic SFN, 10 mM 3-MA or a combination of 40 µM synthetic SFN and 10 mM 3-MA. Untreated control cells were also included in the experiments. After 48 h, the MTT assay was performed on the cells, as described above. The measurements were run in triplicate and the experiments were repeated three times.
Lactate dehydrogenase (LDH) activity measurement. The BE(2)-C cells (2.5x10 4 /well) were cultured in 96-well plates for 24 h. The medium was then removed and the cells were treated with either 40 µM synthetic SFN, 10 mM 3-MA or a combination of 40 µM synthetic SFN and 10 mM 3-MA. Untreated control cells were also included in the experiments. After 48 h, the cell cultures were centrifuged at 250 x g for 10 min at room temperature. The medium was removed and the cells were lysed using 1% Triton-X 100 (Sigma-Aldrich) in serum-free culture medium. LDH activity was measured using the Cytotoxicity Detecion kit (LDH) from Roche Diagnostics (Warsaw, Poland) according to the manufacturer's instructions. The measurements were run in triplicate and the experiments were repeated three times.
Crystal violet staining. The BE(2)-C cells (2.5x10 4 /well) were cultured in 96-well plates for 24 h. The medium was then removed and the cells were treated with either 40 µM synthetic SFN, 10 mM 3-MA or a combination of 40 µM synthetic SFN and 10 mM 3-MA. Untreated control cells were also included in the experiments. After 48 h, the cells were collected and centrifuged at 250 x g for 10 min at room temperature. The culture medium was then removed, the cells were fixed with 0.1% crystal violet (Sigma-Aldrich) in 20% ethanol (Sigma-Aldrich) for 10 min and washed once with distilled water. The cells were observed using a Nikon Eclipse TS100 microscope (Nikon Corooration, Tokyo, Japan). Images of the cells were captured using a digital camera (Canon Powershot A1200; Canon, Inc., Tokyo, Japan).
Thymidine incorporation. A thymidine incorporation assay was performed in order to measure the rate of DNA synthesis. The BE(2)-C cells were seeded in a 24-well plate (1.6x10 5 cells/well) and allowed to attach. After 24 h the medium was refreshed and the indicated concentrations of SFN (10-100 µM) were added. The cells treated with media alone were used as control cells. Following a 24-h incubation, the media was replaced with 400 µl isotope solution (activity, 1 µCurie/ml). The samples were prepared according to the methods by Riss and Sirbasku (20) . After 24 h, the cells were fixed with 800 µl cold (4˚C) methanol-acetic acid solution (3:1 proportion; POCH, Gliwice, Poland). The solution was then aspirated and each well was washed with 80% methanol and dried for 30 min at room temperature. A total of 125 µl trypsin was added to each well and incubated for 30 min at 37˚C. Following incubation, 125 µl 1% SDS solution (Sigma-Aldrich) was added and plates were incubated for 30 min at 25˚C. Finally, 20 µl of each sample was mixed with 3 ml scintillator carrier (Akwascynt, POCH). The measurements were performed using the 1211 Rackbeta Liquid Scintillation Counter (LKB Wallac; LKB Instruments, Victoria, Australia). Four cycles of measurements were performed and the first measurement was discarded. The results are presented as plots of counts per minute for 1 µg of whole-cell protein content. The protein concentration was determined using the bicinchoninic acid assay, according to the manufacturer's instructions (Sigma-Aldrich). The measurements were run in triplicate and the experiment was repeated three times.
Caspase activation assay. The activation of caspases 2, 3, 6, 7, 8, 9 and 10 was determined using the Homogeneous Caspases Assay (Roche Diagnostics) according to the manufacturer's instructions. The BE(2)-C cells (4x10 4 ) were seeded onto 96-well plates with black sides and a transparent, flat bottom (Corning-Costar, Corning, NY, USA), and allowed to attach. Following a 24-h incubation, the medium was replaced and the cells were treated with either the medium alone (control) or the indicated concentrations of SFN and/or 3-MA for the indicated periods of time. The samples were tested in duplicate, the fluorescent signals were measured using the Infinite ® 200 PRO multimode reader (Tecan Group Ltd, Maennedorf, Switzerland).
Immunoblotting. The BE(2)-C cells (1x10 6 ) were grown on 55-mm diameter plates and treated with SFN and/or 3-MA, as described above. Whole cell extracts were obtained according to the methods of Sadowski et al (21) . Briefly, following the indicated period of incubation, the media was removed and the cells were collected in cold phosphate-buffered saline (PBS), then washed with PBS and centrifuged at 140 x g for 5 min at 4˚C. The samples were then resuspended in 70-100 µl lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate, 2 mM EDTA, 1 mM Na 3 VO 4 , 5 mM NaF, 1 mM dithiothreitol, 1 mM phenylmethanesulfonylfluoride; 10% glycerol) and incubated on ice for 20 min. All reagents were purchased from BioShop Canada, Inc., (Burlington, ON, Canada). The lysates were aspirated through a syringe (0.6-mm diameter) and centrifuged at 11,400 x g for 5 min at 4˚C. The supernatants were collected and stored at -20˚C until further use. The protein lysates were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Hybond P; Merck Millipore, Warsaw, Poland). The membranes were treated with a solution containing 10 mM Tris (pH 7.4; BioShop Canada), 150 mM NaCl (POCH), 0.05% Tween ® 20 (Sigma-Aldrich) and 5% nonfat dry milk (Cell Signalling Technology, Inc.) and incubated with the desired primary antibody for 1 h at room temperature. Antibodies, raised against human antigens, included rabbit monoclonal anti-beclin-1 antibody (1:1,000) and rabbit monoclonal anti-LC3B antibody (1:1,000), from Cell Signaling Technology, Inc. Rabbit polyclonal anti-Bcl-2 antibody (DC 21, 1:1,000; sc-783) and mouse monoclonal anti-Bax antibody (B-9, 1:1,000; sc-7480) from Santa Cruz Biotechnology, Inc. and mouse monoclonal anti-GAPDH antibody G8795 (1:40,000) from Sigma-Aldrich. Following incubation with these primary antibodies, the membranes were washed three times for 5 min with the solution containing 10 mM Tris (pH 7.4), 150 mM NaCl with 0.1 % Tween® 20. After the washing steps, the membranes were treated with the appropriate HRP-conjugated secondary antibodies for 1 h at room temperature. The secondary antibodies with indicated dilutions were as follows: rabbit anti-mouse IgG-HRP, A9044, 1:50,000 (Sigma-Aldrich); goat anti-rabbit IgG-HRP, A0545, 1:20,000 (Sigma-Aldrich); goat anti-rabbit IgG-HRP, #7074, 1:2,000 (Cell Signaling Technology). After secondary antibodies incubation, membranes were washed as described above. The immunoreactive bands were visualized using an Enhanced Chemiluminescence substrate (Immobilon Western HRP substrate; Merck Millipore), according to the manufacturer's instructions. The intensity of the immunoreactive bands was determined by densitometric scanning in order to quantify the changes to the protein expression levels (Quest Spot Cutter, Quantity One, version 4.6.9 software; Bio-Rad Laboratories, Hercules, CA, USA). The experiment was repeated between two and four times and representative results are shown.
Flow cytometric analysis of the mitochondrial membrane potential. To measure the mitochondrial membrane potential (∆ψ m ) in the neuroblastoma cells, flow cytometric analyses were performed using the MitoTracker ® Red CMXRos dye (Invitrogen Life Technologies, Carlsbad, CA, USA). The cells were plated and treated as described above. Cells treated with 60 µM STS, an unspecific protein kinase inhibitor, were used as a positive control. The CMXRos staining protocol was performed as follows. The BE(2)-C cells were collected, centrifuged at 250 x g for 10 min at 4˚C and stained with 1 ml 500 nM CMXRos solution per 1 ml cell suspension [in medium with 10% fetal bovine serum (FBS), 15 min, 37˚C]. The cells were then washed twice with media supplemented with 2% FBS and resuspended in 0.5 ml media. The cells were analyzed using a FACScan (BD Biosciences, Franklin Lakes, NJ, USA). The experiment was repeated three times. 
Results

SFN-induced inhibition of the growth of BE(2)-C cells.
In order to determine the inhibitory influence of SFN on the BE(2)-C neuroblastoma cell line, the cells were cultured with increasing concentrations of the synthetic isothiocyanate (5-100 µM) for 24 and 48 h. Untreated cells were also included. The IC 50 -value after 24 h was calculated as 38 µM (data not shown). Therefore, based on earlier assays and previously published results (8, 22) , 40 µM SFN was subsequently selected for further experiments. Microscopic evaluation (data not shown) and crystal violet staining of the SFN-treated cells suggested that SFN treatment caused cell death and after 48 h, the cells began to detach from the culture dish (Fig. 1A) . Combinatorial treatment of the cells with SFN with 3-MA resulted in a marked detachment of cultured cells. Treatment with 3-MA alone did not alter the morphology of the cells. To assess the cytotoxicity of SFN on the cells, the cell viability was analyzed using an MTT assay (Fig. 1B) . The inhibitory effects of SFN were clearly visible at 48 h. Treatment of the BE(2)-C cells with 40 µM SFN also resulted in decreased cellular levels of LDH, a cytosolic enzyme that leaks from damaged cells (Fig. 1C) . Treatment with 3-MA slightly decreased the viability of the cells, as estimated by MTT assay, crystal violet staining and analysis of LDH activity (Fig. 1) . However, the combined treatment with SFN and 3-MA resulted in a statistically significant decrease in the cellular parameters measured as compared with SFN treatment alone ( Fig. 1B and C ; P<0.05 and P<0.01, respectively).
Purified broccoli sprout extracts containing ~90% SFN, used in our preliminary studies, have also shown potent inhibitory effects on the growth of numerous human cancer cell lines, including BE(2)-C neuroblastoma, HepG2 hepatoma and SK-MEL-28 melanoma (data not shown).
SFN induces caspase activation and decreases DNA content in neuroblastoma cells.
To investigate whether apoptosis may be responsible for the decreased survival of the BE(2)-C cells treated with SFN, total activity of caspases 2, 3, 6, 7, 8, 9 and 10 was assayed. The cells (4x10 4 per well) were cultured in the presence of 40 µM SFN for 48 h. Treatment with SFN resulted in a significant ~1.5-fold increase in the total activity of caspases 2, 3, 6, 7, 8, 9, and 10 ( Fig. 2A; P<0 .05) compared with the control cells. Furthermore, treatment with autophagy inhibitor 3-MA (10 mM) increased caspase activity when used alone ( Fig. 2A) . This effect was expected, as the inhibition of autophagy may be associated with increased apoptotic cell death (23) . However, treatment with a combination of 3-MA and 40 µM SFN resulted in a significant decrease in caspase activity, possibly due to prolonged incubation with high doses of SFN and 3-MA ( Fig. 2A; P<0 .01), compared with the control cells and to single agents treatments. As the exact types of caspases involved in the process cannot be distinguished by the test used in the present study, it is possible that caspases of the receptor and mitochondrial pathways are involved in SFN-induced apoptosis (7).
The higher concentrations of SFN also inhibited DNA synthesis. The effects of SFN on its ability to repress 3 H-thymidine incorporation into DNA were studied at four different concentrations (10, 50, 75 and 100 µM). The rate of 3 H-thymidine incorporation decreased significantly with increasing SFN concentration ( Fig. 2B; P<0 .001) compared with the control cells. This result is concordant with previous findings reported by Rajendran et al (10) , which showed that SFN may cause a severe decrease in DNA content in HCT116 cells treated with 15 µM SFN for 24 h.
Analysis of LC3 protein modification.
To investigate whether autophagy may be induced by SFN treatment in the (2)-C cells, the proteolytic process of MAP LC3 (in short LC3) was assessed. The conversion from the endogenous, cytosolic LC3-I protein to the LC3-II protein, which binds to autophagosomal membranes, was detected by immunoblotting with antibodies against LC3 (13, 15) . These results may provide evidence of early autophagy induction. The cells were treated with 40 µM SFN, 10 mM 3-MA or the two agents simultaneously for 6, 24 and 48 h, and the isolated whole cells extracts were subjected to western blot analysis (Fig. 3) . Treatment with SFN led to increased protein expression levels of LC3-I and II at 6, 24 and 48 h (P<0.05) compared with the SFN-treated cells compared with the control cells. These results suggested the involvement of the autophagic process, since the amount of LC3-II usually correlates well with the number of autophagosomes (16) . Simultaneous treatment of SFN with 3-MA also resulted in increased expression levels of the two forms of LC3, compared with the control cells, from as early as 6 h and the tendency remained unchanged up to 48 h ( Fig. 3A and C; P<0 .05). 3-MA treatment alone was used as a control and caused a moderate change in the LC3 protein expression pattern, suggesting that autophagy induction was almost completely blocked. In addition, microscopic observation of the SFN and 3-MA treated cells suggested that the treatment caused cell death and after 48 h the cells began to detach from the culture dish (Fig. 1A) .
SFN elevates Bax protein expression levels in neuroblastoma cells.
In order to further investigate the mechanisms of the observed cell death, the BE(2)-C cells were treated with SFN and 3-MA and the protein expression levels of the antiapoptotic gene Bcl-2 were measured (Fig. 4) . After 6, 24 and 48 h of SFN treatment, the protein expression levels of Bcl-2 remained unchanged. Combined treatment of SFN with 3-MA decreased the protein expression levels of Bcl-2 as compared with SFN treatment alone (Fig. 4A) . Treatment with 3-MA alone decreased the Bcl-2 protein expression levels, particularly at 48 h; however this change was not statistically significant. Furthermore, the protein expression levels of another autophagic factor, beclin-1, were measured and shown to remain unchanged following treatment with the agents tested (Fig. 4B) . In addition, Bax protein expression levels were evaluated by immunoblotting and increased levels were Fig. 4C; P<0 .05). Changes in the Bax protein levels were statistically significant at 24 h, suggesting the induction of apoptosis.
Analysis of mitochondrial membrane potential in SFN-treated neuroblastoma cells. Flow cytometry was used to measure changes to the mitochondrial membrane potential upon treatment with SFN. CMXRos served as a dye, which actively accumulates in the mitochondria of live cells. Control cells with functional mitochondrial membranes had a high accumulation of CMXRos ( Fig. 5A; channel P3 ). The positive control apoptotic cells had a significant loss in mitochondrial membrane potential and were obtained following treatment with 60 µM STS, a known proapoptotic compound, for 24 h (channel P5). As compared with STS treatment, treatment with 40 µM SFN also caused a significant decrease in the mitochondrial membrane potential (Fig. 5A) . Treatment with 3-MA alone caused only a minimal decrease in mitochondrial membrane potential, but did not alter the effects of SFN.
In addition, the cells were cultured for 3, 6 and 24 h in the presence of 40 µM SFN, 10 mM 3-MA or 60 µM STS. No effect was observed on the mitochondrial membrane depolarization in response to treatment with any of the compounds at 3 h (Fig. 5B) , whereas an increase in depolarization was observed in response to STS treatment for 6 h. A significant increase in the number of cells with depolarized mitochondrial membranes was observed in response to treatment with SFN for 24 h and was comparable with the increase caused by STS and combined treatment of SFN with 3-MA. Treatment with 3-MA alone did not affect mitochondrial membrane depolarization.
Discussion
The present study aimed to determine how neuroblastoma cells respond to the potential anticancer agent SFN, as well as 3-MA, an inhibitor of autophagy. Naturally occurring isothiocyanates of cruciferous origin have previously been shown to inhibit carcinogenesis (2, 4) . They may therefore be considered as potential protective and therapeutic agents. Despite intensive treatment, neuroblastoma tumors are difficult to eradicate and >60% of children above the age of one year with neuroblastoma have poor prognosis (24, 25) . Naturally occurring compounds, such as SFN, may be used as a supplementary treatment for cancer therapy, or may be used in combination with conventional therapeutics. It was previously shown that administration of SFN to female rats, through gavage, resulted in a maximum concentration of the compound in the blood and mammary glands as early as at 1 h, reducing the incidence, multiplicity and weight of mammary tumors (1) . Therefore, it is likely that the concentration of SFN required to induce cell death may be achievable in humans (7). 
A B C
In the present study, 40 µM SFN induced apoptosis of BE(2)-C cells after 24 and 48 h of treatment, as determined by a decrease in the mitochondrial membrane potential, an increase in caspase activity and inhibition of DNA synthesis. Flow cytometry showed that treatment with SFN decreased the mitochondrial membrane potential in ~40% of cells at 24 h, and ~62% of cells at 48 h. Due to its electrophilic nature, SFN may directly modify nucleophilic sites, such as sulfhydryl groups, in mitochondrial respiratory chain enzymes or mitochondrial membranes. Conversely, a previous study reported that apoptosis was inhibited in the PC-3 and LNCaP human prostate cancer cells lines through autophagy induced by treatment with SFN (8) . SFN was shown to induce the formation of acidic vesicle organelles, which enclosed whole mitochondria and inhibited apoptosis in the prostate cell lines. Mitochondrial digestion within autophagosomes prevents the leakage of cytochrome c into the cytoplasm and consequently blocks the induction of apoptosis (8) . In the present study, SFN induced autophagy and apoptosis, as documented by an increase in LC3II expression levels, as well as caspase activation, an increase in Bax expression levels and loss of mitochondrial membrane potential, respectively. The two forms of LC3, I and II, were increased upon treatment with SFN, and combined treatment with 3-MA resulted in even higher levels at 24 h. Therefore, it may be concluded that SFN causes autophagy by a mechanism independent of autophagy inhibition by 3-MA. However, in the present study, fluorescent fusion methods were not used to determine the protein fate of LC3 within neuroblastoma cells. This method is expected to provide clear evidence of autophagosomal formation.
In the PC-3 prostate cancer cell line, SFN was previously shown to increase the Bax/Bcl-2 ratio, favoring apoptosis (26) . Similar conclusions may be drawn from the results of the present study, as Bax protein expression levels were increased early upon treatment with SFN and remained high at up to 48 h. In addition, in the BE(2)-C cells, a negligible change in the protein expression levels of Bcl-2 was observed, thus increasing the Bax/Bcl-2 ratio. Similarly, the lack of stimulatory effects of SFN on Bcl-2 expression levels were demonstrated in a previous study on the Jurkat T-cell lymphoma cell line (6) . Beclin-1 interacts with class III PI3K complex and participates in autophagosomal formation (27, 28) . In the present study, the protein expression levels of beclin-1 remained unchanged in response to treatment with SFN and 3-MA, or a combination of the two, at 6 h. At later time-points, only slight inhibitory effects on the expression levels of beclin-1 were observed in response to combined treatment. These results indicated that beclin-1 was constitutively expressed in the BE(2)-C neuroblastoma cells.
Apoptosis and autophagy are precisely regulated and have important roles in the maintenance of homeostasis and disease. Therefore, it is important to distinguish the effects of any potential anti-cancer agent on these two processes. An enhanced understanding of the role of SFN in the induction of cell death may have implications in the design of future clinical trials for combination cancer treatments using SFN and conventional anti-cancer drugs (24, 25) . The inhibition of autophagy is also an attractive therapeutic approach, since inhibition of autophagy in cancer cells is associated with increased apoptotic cell death (8, 23) . It has previously been reported that the combination of SFN with autophagy inhibition, by 3-MA or bafilomycin A1, may be a promising strategy for breast cancer (29) , human colon cancer (30) or human prostate cancer (8) therapy. Furthermore, the chemopreventive efficacy of SFN may be augmented by inhibition of autophagy using chloroquine in a transgenic adenocarcinoma of mouse prostate as shown in an in vivo study (31) . The present study showed that the inhibition of autophagy by 3-MA does not alter A B SFN-induced autophagy and apoptosis in human neuroblastoma cells, although the combined effect of SFN and 3-MA is evidenced by a significant decline in cell viability.
